Product Description
Johnson & Johnson is developing Tianeptine as an antidepressant drug. (Sourced from: https://www.cdc.gov/mmwr/volumes/67/wr/mm6730a2.htm)
Mechanisms of Action: SSR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Bosnia | Brazil | Bulgaria | Chile | Croatia | Czech | Dominican Republic | Egypt | Estonia | France | Greece | Hong Kong | Hungary | India | Indonesia | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Morocco | Pakistan | Peru | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Thailand | Tunisia | Turkey | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: Eastern America
Company Founding Year: 1886
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Depressive Disorder, Major
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05686408 |
UPLIFT | P2 |
Completed |
Depressive Disorder, Major |
2023-09-29 |
52% |
2023-12-12 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |